Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-08-01
2010-06-08
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S450000
Reexamination Certificate
active
07732484
ABSTRACT:
Disclosed is the use of selective adenosine A1allosteric enhancers to induce angiogenesis at a desired location for treating conditions in which increased angiogenesis is desired, such as stroke, heart disease and peripheral vascular disease.
REFERENCES:
patent: 4877876 (1989-10-01), Tsuji et al.
patent: 5189049 (1993-02-01), Frehel et al.
patent: 5256398 (1993-10-01), McAfee et al.
patent: 5504090 (1996-04-01), Neely
patent: 5733916 (1998-03-01), Neely
patent: 5854081 (1998-12-01), Linden et al.
patent: 5877180 (1999-03-01), Linden et al.
patent: 5939432 (1999-08-01), Baraldi
patent: 6060481 (2000-05-01), LaNoue et al.
patent: 6117445 (2000-09-01), Neely
patent: 6117878 (2000-09-01), Linden
patent: 6177444 (2001-01-01), Baraldi
patent: 6232297 (2001-05-01), Linden et al.
patent: 6251922 (2001-06-01), Jahne et al.
patent: 6303619 (2001-10-01), Linden
patent: 6440947 (2002-08-01), Barron et al.
patent: 6448235 (2002-09-01), Linden et al.
patent: 6476059 (2002-11-01), Jahne et al.
patent: 6514949 (2003-02-01), Linden et al.
patent: 6545002 (2003-04-01), Linden et al.
patent: 6670334 (2003-12-01), Linden et al.
patent: 6713638 (2004-03-01), Linden et al.
patent: 7019027 (2006-03-01), Linden et al.
patent: 2002/0082240 (2002-06-01), Linden et al.
patent: 2002/0111327 (2002-08-01), Linden et al.
patent: 2003/0078248 (2003-04-01), Linden et al.
patent: 2003/0186926 (2003-10-01), Linden et al.
patent: 2003/0212082 (2003-11-01), Linden et al.
patent: 2004/0180948 (2004-09-01), Linden et al.
patent: 2005/0027125 (2005-02-01), Linden et al.
patent: 2005/0182018 (2005-08-01), Linden et al.
patent: 2005/0261236 (2005-11-01), Okusa et al.
patent: 2006/0040888 (2006-02-01), Rieger et al.
patent: 2006/0040889 (2006-02-01), Rieger et al.
patent: 2006/0100169 (2006-05-01), Rieger et al.
patent: 0497258 (1992-08-01), None
patent: 0 503 563 (1992-09-01), None
patent: 0970696 (2000-01-01), None
patent: 1 084 710 (2001-03-01), None
patent: WO 98/06845 (1996-03-01), None
patent: WO 98/57651 (1998-12-01), None
patent: WO 99/21617 (1999-05-01), None
patent: WO 99/24450 (1999-05-01), None
patent: WO 99/34803 (1999-07-01), None
patent: WO 99/38532 (1999-08-01), None
patent: WO 00/02596 (2000-01-01), None
patent: WO 01/10391 (2000-03-01), None
Xu et al., FASEB, 8(4-5) (1994), A79.
Desseau et al., Circulation Research, 59(2), (Aug. 1986), pp. 163-169.
D'Ancona, S. et al., Effect of Dipyridamola, 5′-(N-Ethyl)-carboxamidaodenosine and 1,3-Dipropyl-8-(2-amino-4-chlorophenyl)-xanthine on LOVO Cell Growth and Morphology, Anticancer Research, vol. 14, No. 1A, pp. 93-97, Jan. 1994.
Neely, et al. “A1 Adenosine Receptor Antagonists Block Ischemia-reperfusion Injury of the Heart” Circulation. 94(9)[suppl II]:II-376-II-380 (1996).
Neely et al. A1 adenosine “Receptor Antagonists Block Ischemia-reperfusion Injury of the lung.” Am. J. Physiol. 268 (Lung Cell. Mol. Physiol. 12):L1036-L1046 (1995).
Database Medline on STN, (Columbus, OH, USA), No. 96223462, Martin P. et al. Characterization of 8-(N-methylispropyl)amino-N6-(5′-endohydroxy- endonobornyl)-9-methyladenine (WRC-0571), a highly potent and selective, non-xanthine antagonist of A1 adenosine receptors, abstract, J. Pharmacol. and Exp. Therap., Feb. 1996, 276 (2), 490-9.
Burckhartt, B. et al., “Acadesine Extends the Window of Protection Afforded by Ischaemic Preconditioning in Conscious Rabbits,” Cardiovascular Research, vol. 29, No. 5, 1995, pp. 653-657.
Grant, M.B. et al., “Adenosine Receptor Activation Induces Vascular Endothelial Growth Factor in Human Retinal Endothelial Cells,” Circulation Research, vol. 85, No. 8, 1999, pp. 699-706.
Halle, J.N. et al., “Enhancing Adenosine A1 Receptor Binding Reduces Hypoxiolschemic Brain Injury in Newborn Rats,” Brain Research, vol. 759, No. 2, 1997, pp. 309-312.
Mizumura, T. et al., “PD 81,723, an Allosteric Enhancer of the A1 Adenosine Receptor, Lowers the Threshold for Ischemic Preconditioning in Dogs,” Circulation Research, vol. 79, No. 3, 1996, pp. 415-423.
Picano, E. et al., “European Stroke Prevention Study-2 Results: Serendipitous Demonstration of Neuroprotection Induced by Endogenous Adenosine Accumulation?” Trends in Pharmacological Sciences, vol. 19, No. 1, 1998, pp. 14-16.
Adamis, A. P. et al., “Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia-Associated Iris Neovascularization in a Nonhuman Primate,” Arch. Ophthalmol., vol. 114, pp. 68-71, 1996.
Aguilar, J. S. et al., “Isolation and Characterization of an Avian A1Adenosine Receptor Gene and a Related cDNA Clone,” Biochem. J., vol. 307, pp. 729-734, 1995.
Baumgartner, I. et al., “Constitutive Expression of phVEGF165after Intramuscular Gene Transfer Promotes Collateral Vessel Development in Patients with Critical Limb Ischemia,” Circulation, vol. 97, No. 12, pp. 1114-1123, 1998.
Barnhill, R. L. et al., “Biochemical Modulation of Angiogenesis in the Chorioallantoic Membrane of the Chick Embryo,” Journal of Investigative Dermatology, vol. 81, No. 6, pp. 485-488, 1983.
Belardinelli, L. et al., “The Cardiac Effects of Adenosine,” Progress in Cardiovascular Diseases, vol. 21, No. 1, pp. 73-97, 1989.
Bruns, R. F. et al., “Allosteric Enhancement of Adenosine A1Receptor Binding and Function by 2-Amino-3-Benzoylthiophenes” Molecular Pharmacology, vol. 38, pp. 939-949, 1990.
Bruns, R. F. et al., “Structure-Activity Relationships for Enhancement of Adenosine A1Receptor Binding by 2-Amino-3-Benzoylthiophenes,” Molecular Pharmacology, vol. 38, pp. 950-958, 1990.
Dusseau, J. W. et al., “Hypoxia-Induced Angiogenesis in Chick Chorioallantoic Membranes: A Role for Adenosine,” Respiration Physiology, vol. 71, pp. 33-44, 1988.
Dusseau, J. W. et al., “Stimulation of Angiogenesis by Adenosine on the Chick Chorioallantoic Membrane,” Circulation Research, vol. 59, pp. 163-170, 1986.
Fischer, S. et al., “Expression of Vascular Permeability Factor/Vascular Endothelial Growth Factor in Pig Cerebral Microvascular Endothelial Cells and its Upregulation by Adenosine,” Molecular Brain Research, vol. 28, pp. 141-148, 1995.
Folkman, J. et al., “Angiogenesis,” Journal of Biological Chemistry, vol. 267, No. 16, pp. 10931-10934, 1992.
Fredholm, B. B. et al., “International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors,” Pharmacological Reviews, vol. 53, No. 4, pp. 527-552, 2001.
Grant, M. B. et al., “Adenosine Receptor Activation Induces Vascular Endothelial Growth Factor in Human Retinal Endothelial Cells,” Circulation Research, vol. 85, pp. 699-706, 1999.
Grant, M. B. et al., “Adenosine Mediates Human Retinal Endothelial Cell (HREC) Chemotaxis, Capillary Tube Formation and Stimulatory Cell Signaling Cascades (abstract),” IOVS, vol. 40, No. 4, 3240-B98, 1999.
Hood, J. et al., “Protein Kinase G Mediates Vascular Endothelial Growth Factor-Induced Raf-1 Activation and Proliferation in Human Endothelial Cells,” Journal of Biological Chemistry, vol. 273, No. 36, pp. 23504-23508, 1998.
Iliodromitis, E. K. et al., “The PKC Activator PMA Preconditions Rabbit Heart in the Presence of Adenosine Receptor Blockade: Is 5′-Nucleotidase Important?” J. Mol. Cell Cardiol., vol. 30, pp. 2201-2211, 1998.
Jonzon, B. et al., “Adenosine Receptor-Mediated Changes in Cyclic AMP Production and DNA Synthesis in Cultured Arterial Smooth Muscle Cells,” Journal of Cellular Physiology, vol. 124, pp. 451-456, 1985.
Leitman, D. C. et al., “Forskolin, Phosphodiesterase Inhibitors, and Cyclic AMP Analogs Inhibit Proliferation of Cultured Bovine Aortic Endothelial Cells,” Journal of Cellular Physiology, vol. 127, pp. 237-243, 1986.
Linden, J., “Cloned Adenosine A3Receptors: Pharmacological Properties, Species Differences and Receptor Functions,” TiPS, vol. 15, pp. 298-306, 1994.
Meininger
Linden Joel
Price Richard
Tucker Amy L.
Youkey Rebecca
Kilpatrick & Stockton LLP
Spivack Phyllis G.
University of Virginia Patent Foundation
LandOfFree
Use of selective adenosine A 1 receptor allosteric... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of selective adenosine A 1 receptor allosteric..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of selective adenosine A 1 receptor allosteric... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4244740